Target INR for Mitral Valve Disease with Chronic Atrial Fibrillation
For patients with mitral valve disease and chronic atrial fibrillation, the target INR is 2.5 (range 2.0-3.0).
Primary Recommendation
The most recent and authoritative guidelines consistently recommend an INR target of 2.5 with a therapeutic range of 2.0-3.0 for patients with mitral valve disease (specifically rheumatic mitral stenosis or mitral regurgitation) who have atrial fibrillation 1, 2, 3, 4, 5. This applies to native valve disease, not mechanical prostheses.
Key Evidence Supporting This Target
The 2014 AHA/ACC/HRS guideline explicitly states that for patients with nonvalvular AF and prior stroke, TIA, or elevated stroke risk, warfarin with an INR of 2.0-3.0 is recommended 2. The 2006 ACC/AHA/ESC guidelines specifically identify rheumatic mitral stenosis as one of the highest risk factors for stroke in AF patients, warranting chronic oral anticoagulation with a target INR of 2.0-3.0 1.
Multiple guidelines from the American Geriatrics Society and stroke prevention literature confirm that patients with rheumatic mitral valve disease and atrial fibrillation require long-term warfarin therapy with an INR target of 2.5 (range 2.0-3.0) 4, 3, 4.
Important Distinctions
Native Valve Disease vs. Mechanical Prostheses
- Native mitral valve disease with AF: INR 2.0-3.0 (target 2.5)
- Mechanical mitral valve prosthesis: INR 2.5-3.5 (target 3.0) - this is a higher intensity due to the prosthetic valve itself 6, 7
The distinction is critical: mechanical valves require higher anticoagulation intensity regardless of AF status.
When Higher Intensity May Be Considered
The evidence shows some nuance regarding anticoagulation intensity. One research study (NASPEAF sub-analysis) found that in mitral stenosis patients with prior embolism, an INR of 2.0-3.0 alone may not provide adequate protection, and combined therapy with antiplatelet agents reduced vascular events by 58.3% 8. However, this conflicts with guideline recommendations that generally advise against routinely adding antiplatelet therapy due to increased bleeding risk 3.
A recent 2025 study from Thailand examining Southeast Asian patients with moderate-to-severe rheumatic mitral stenosis found that while standard INR (2.0-3.0) had comparable net adverse clinical events to high-intensity INR (2.5-3.5), the higher intensity reduced thromboembolism but increased major bleeding 9. This suggests the standard range remains appropriate for most patients.
Monitoring Requirements
- INR should be checked at least weekly during initiation of therapy 1, 2
- Monthly monitoring when stable and within therapeutic range 1, 2
- Target maintaining time in therapeutic range (TTR) >70%, ideally >80% 10
Poor TTR (<80%) is associated with significantly higher rates of bleeding, stroke, and mortality in patients with valve disease and AF 10.
Clinical Pitfalls to Avoid
Do not use DOACs (direct oral anticoagulants): The 2024 ESC guidelines and 2014 AHA/ACC guidelines explicitly state that DOACs are not recommended for patients with moderate-to-severe mitral stenosis - only warfarin or other vitamin K antagonists should be used 2, 11. DOACs are contraindicated in rheumatic mitral stenosis.
Do not routinely add aspirin: Unless there is a separate indication (such as coronary artery disease), adding antiplatelet therapy to warfarin increases bleeding risk without clear benefit in most patients 3.
Distinguish valve type: Ensure you're treating native valve disease (INR 2.0-3.0) versus mechanical prosthesis (INR 2.5-3.5).
Consider recurrent embolism: If patients experience recurrent thromboembolism despite adequate anticoagulation at INR 2.0-3.0, consider increasing the target to 3.0 (range 2.5-3.5) or adding low-dose aspirin 81 mg daily 4.
Special Populations
For patients with large left atrium (≥55 mm) and mitral valve disease even in normal sinus rhythm, warfarin with INR target 2.5 (range 2.0-3.0) should be considered due to increased thromboembolic risk 4, 5, 4.